Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PathoGenesis IPO will support Phase III inhaled tobramycin trials.

Executive Summary

PATHOGENESIS IPO WIL FUND INHALED TOBRAMYCIN DEVELOPMENT as well as other research programs at the Seattle-based start-up firm. PathoGenesis began Phase III clinical trials in July of PA-1005 to treat chronic pseudomonal bacterial lung infections in cystic fibrosis patients. PA-1005 is "a novel, stable, premixed formulation of the antibiotic tobramycin for delivery by inhalation," a Sept. 20 initial public offering prospectus explains.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027000

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel